既往乙型肝炎核心抗体阳性与非酒精性脂肪性肝病的肝硬化及肝细胞癌相关
这项多中心研究分析489例活检证实的非酒精性脂肪性肝病(NAFLD)患者及69例NAFLD相关或隐源性肝细胞癌(HCC)患者,发现抗-HBc阳性与肝硬化风险升高独立相关(校正OR 2.232,95%CI 1.202-4.147),且随访中HCC或肝硬化并发症发生率更高(6.5% vs 2.2%,P=0.039)。
要点
- 抗-HBc阳性NAFLD患者肝硬化比例更高(18.8% vs 7.5%,P<0.001)。
- 抗-HBc阳性与肝硬化关联在校正年龄和代谢因素后仍显著。
- NAFLD相关或隐源性HCC患者中73.9%抗-HBc阳性,均无血清HBV DNA阳性。
核心结论
- 抗-HBc阳性与NAFLD患者肝硬化相关,并可能与非酒精性脂肪性肝病相关肝细胞癌及肝硬化并发症相关。
研究设计与样本
- 多中心研究,纳入489例活检证实的NAFLD患者和69例NAFLD相关或隐源性HCC患者,检测抗-HBc以反映既往HBV感染。
主要发现
- 活检队列中抗-HBc阳性者脂肪变分级更低但纤维化分期更高。
- 抗-HBc阳性与阴性患者肝硬化比例分别为18.8%和7.5%(P<0.001)。
- 校正年龄和代谢因素后,抗-HBc与肝硬化的关联仍显著(校正OR 2.232;95%CI 1.202-4.147)。
- 平均随访6.2年,抗-HBc阳性患者HCC或肝硬化并发症发生率更高(6.5% vs 2.2%;P=0.039)。
- NAFLD相关或隐源性HCC患者中73.9%抗-HBc阳性,且所有患者血清HBV DNA均阴性。
关键数值与推荐
- 抗-HBc阳性与肝硬化关联的校正OR为2.232(95%CI 1.202-4.147)。
- 抗-HBc阳性与阴性患者肝硬化比例分别为18.8%与7.5%(P<0.001)。
- 随访期间抗-HBc阳性与阴性患者HCC或肝硬化并发症发生率分别为6.5%与2.2%(P=0.039)。
- NAFLD相关或隐源性HCC患者中抗-HBc阳性比例为73.9%。
临床怎么用
- 对NAFLD患者可检测抗-HBc以识别肝硬化及HCC风险可能更高的亚群。
- 抗-HBc阳性且无血清HBV DNA阳性的NAFLD患者仍需关注肝硬化和HCC风险。
- 未来研究需明确抗-HBc在筛选非肝硬化NAFLD患者进行HCC监测中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Previous exposure to hepatitis B virus (HBV) may increase the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C. We aim to study the impact of previous HBV infection on the severity and outcomes of patients with nonalcoholic fatty liver disease (NAFLD). METHODS: This was a multicenter study of 489 patients with biopsy-proven NAFLD and 69 patients with NAFLD-related or cryptogenic HCC. Antihepatitis B core antibody (anti-HBc) was used to detect the previous HBV infection. RESULTS: In the biopsy cohort, positive anti-HBc was associated with lower steatosis grade but higher fibrosis stage. 18.8% and 7.5% of patients with positive and negative anti-HBc had cirrhosis, respectively (P < 0.001). The association between anti-HBc and cirrhosis remained significant after adjusting for age and metabolic factors (adjusted odds ratio 2.232; 95% confidence interval, 1.202-4.147). At a mean follow-up of 6.2 years, patients with positive anti-HBc had a higher incidence of HCC or cirrhotic complications (6.5% vs 2.2%; P = 0.039). Among patients with NAFLD-related or cryptogenic HCC, 73.9% had positive anti-HBc. None of the patients had positive serum HBV DNA. By contrast, antihepatitis B surface antibody did not correlate with histological severity. DISCUSSION: Positive anti-HBc is associated with cirrhosis and possibly HCC and cirrhotic complications in patients with NAFLD. Because a significant proportion of NAFLD-related HCC may develop in noncirrhotic patients, future studies should define the role of anti-HBc in selecting noncirrhotic patients with NAFLD for HCC surveillance.
引用
- Chan TT, Chan WK, Wong GL, et al. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2020. PMID: 32149781. doi:10.14309/ajg.0000000000000588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。